Overview of the FDA’s Predetermined Change Control Plans for AI-Enabled Medical Devices
Food and Drug Administration (FDA) has established a regulatory framework to facilitate iterative updates of AI-enabled medical devices post-market approval through a structured process known as a Predetermined Change Control Plan (PCCP). The PCCP pathway allows manufacturers to implement modifications to AI-enabled devices without requiring separate marketing submissions for each change, provided the modifications align with the pre-approved plan.
The guidance applies to AI-enabled devices regulated through the 510(k), De Novo, and Premarket Approval (PMA) pathways, including those integrated into combination products. This approach reflects the FDA’s evolving regulatory strategy to accommodate the dynamic nature of AI technologies while maintaining rigorous oversight. The framework is designed to support iterative improvements, such as algorithmic enhancements or data-driven refinements, without compromising patient safety or device efficacy.
Key Components of a Predetermined Change Control Plan
A PCCP must include several critical elements to ensure transparency, accountability, and regulatory compliance.
- These modifications must be justified based on their potential to improve device functionality, accuracy, or clinical utility without introducing unacceptable risks.
- Methodology for Development, Validation, and Implementation: The plan must outline the scientific and technical processes used to develop, test, and deploy modifications. This includes validation protocols to ensure that updates maintain or enhance the device’s safety and effectiveness. The methodology should align with established regulatory standards, such as those outlined in the FDA’s Software as a Medical Device (SaMD) guidance.
- Impact Assessment: An evaluation of how each modification may affect device performance, patient outcomes, and overall safety. This assessment should consider potential biases, unintended consequences, or shifts in clinical performance that could arise from algorithmic changes or new data inputs. The FDA emphasizes that modifications should not compromise the device’s intended use or introduce new risks.
The PCCP is reviewed as part of the initial marketing submission for the AI-enabled device. Once approved, manufacturers can implement modifications within the scope of the plan without submitting additional marketing applications, provided they adhere to the pre-defined criteria. This streamlined process reduces regulatory burden while ensuring that updates are systematically evaluated and controlled.
Alignment with the 2025 Draft Guidance on Lifecycle Transparency and Bias Evaluation
The PCCP framework is complemented by the FDA’s 2025 draft guidance on lifecycle transparency and bias evaluation for AI-enabled devices.
- This includes tracking modifications, data sources, and algorithmic decisions throughout the device’s lifecycle.
- Bias Evaluation: The draft guidance introduces requirements for assessing and mitigating biases in AI-enabled devices. This evaluation should be integrated into the PCCP to ensure that modifications do not exacerbate existing biases or introduce new ones.
The combination of PCCPs and the 2025 draft guidance reflects the FDA’s commitment to fostering innovation in AI-enabled medical devices while prioritizing patient safety and equitable healthcare outcomes. With over 1,000 AI-enabled devices already cleared by the FDA, this regulatory approach provides a scalable and adaptive framework for managing the complexities of AI-driven healthcare technologies.
Submission and Public Comment Process
The FDA invites stakeholders, including manufacturers, healthcare providers, and patient advocacy groups, to submit comments on the PCCP guidance. Comments can be submitted online or in written form, with all submissions identified by the docket number FDA-2022-D-2628. The FDA encourages input on how the PCCP framework can be refined to better support innovation while maintaining regulatory rigor.
For those unable to submit comments online, written submissions should be mailed to the FDA’s designated address. The agency’s willingness to accept comments at any time underscores its commitment to an iterative and collaborative regulatory process. This openness to feedback is particularly important for AI-enabled devices, where technological advancements and clinical insights may necessitate ongoing adjustments to regulatory approaches.
Required actions
- Include a description of planned modifications, a modification protocol with validation methods and an impact assessment so approved AI devices can be updated without new submissions - Follow the 2025 draft guidance on transparency, bias evaluation and cybersecurity across the device lifecycle